Futura Medical Announces First Patient Enrolled in European Phase 3 study of MED2002 for the Treatment of Erectile Dysfunction

Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys┬« drug delivery technology currently focused on sexual health and pain, today announces that the first patient has enrolled in the first European Phase 3 study, (“FM57”), of MED2002, a topical glyceryl trinitrate (“GTN”) gel for the treatment of erectile dysfunction (“ED”). The Phase 3 study remains on track, with headline data expected by the end of 2019.

James Barder, Chief Executive Officer of Futura Medical said: “We are pleased to announce the first patient enrolment in our first European Phase 3 trial with MED2002. This is an important milestone for Futura, building on the success of both the Phase 2 and PK data.

“Futura is now in a position to…

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...